Stock Details
FRE.DE is Fresenius SE & Co. KGaA's stock. Stock exchange XETRA (Currency EUR). Average price in 50 days is 24.43โ‚ฌ. Average daily volumn in 3 months 1.52M. Market cap 12.70B



Stock symbol : FRE.DE. Exchange : XETRA. Currency : EUR
Lastest price : 22.55โ‚ฌ. Total volume : 1.54M. Market state POST
Click reload if you want to check the lastest price on market!!!

Fresenius SE & Co. KGaA (FRE.DE)
Last Price
22.55โ‚ฌ
Change
0.73
Volume
1.54M

Previous Close21.82
Open22.33
Day Range22.21-22.59
Bid22.43 x N/A
Ask22.44 x N/A
Volume1.54M
Average Volume1.52M
Market Cap12.7B
Beta1.11
52 Week Range20.98-42.50
Trailing P/E7.39
Foward P/E6.23
Dividend (Yield %)4.19%
Ex-Dividend Date2022-05-16



Financial Details


According to Fresenius SE & Co. KGaA's financial reports the company's revenue in 2021 were 37.52B an increase( +2.78%) over the years 2020 revenue that were of 36.28B. In 2021 the company's total earnings were 1.82B while total earnings in 2020 were 1.71B(0%).


Loading ...



Organization

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi s... egment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Hรถhe, Germany.

Market Cap:
12.70B
Revenue:
37.52B
Total Assets:
71.96B
Total Cash:
2.76B


News about "Fresenius SE & Co. KGaA"

Fresenius SE & Co KGaA

Source from : Reuters - 5 days ago

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for ...See details»


Fresenius Medical Care AG & Co. KGaA ADR

Source from : Wall Street Journal - 21 days ago

Fresenius Medical Care AG & Co. KGaA, Fresenius Management SE, Else Krรถner-Fresenius-Stiftung Dorothea Wenzel Member-Supervisory Board Fresenius Medical Care AG & Co. KGaA, H. Lundbeck A/S ...See details»


Fresenius SE

Source from : Barron's - 1 month ago

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following ...See details»


Fresenius Recalls Dialysis Concentrate, May Be Contaminated

Source from : MD&M East - 14 days ago

Fresenius Medical Care is one of four arms of Fresenius SE & Co. KgaA, which makes its headquarters in Bad Homburg, Germany. The other three business units are Fresenius Kabi, which develops, produces ...See details»


Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius

Source from : Yahoo UK & Ireland - 1 month ago

Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius 19-Aug-2022 / 18:33 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU ...See details»


The Global Biosimilars Market size is expected to reach $59 billion by 2028, rising at a market growth of 24.4% CAGR during the forecast period

Source from : Benzinga.com - 1 days ago

Reportlinker.com announces the release of the report "Global Biosimilars Market Size, Share & Industry Trends Analysis Report By Application, By Type, By Regional ...See details»


IV Bags Market : Analysis by Size, Share Trends, Future Growth, Emerging Trends, Qualitative Outlook and Global Forecast to 2027

Source from : MarketWatch - 5 days ago

The global IV Bags market size was valued at USD 3129.53 million in 2021 and is expected to expand at a CAGR of ...See details»


acute-bacterial-skin-and-skin-structure-infections-market-to-surpass-us-55121-mn-by-2030-image

Acute Bacterial Skin and Skin Structure Infections Market to Surpass US$ 5,512.1 Mn by 2030

Source from : Medgadget - 12 hours ago

Moreover, market players are participating in research and advancement activities for the improvement of new drugs in the treatment of global acute bacterial skin and skin structure infections market.See details»


Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufendยฎ (pegfilgrastim - fpgk)

Source from : Joplin Globe - 28 days ago

Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group. For more information visit the companyโ€™s website at www.fresenius-kabi.com. This release contains ...See details»


Fresenius Medical Care KGAA ST (FMEd)

Source from : Investing - 5 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


General Anesthesia Drugs Market Expected to Raise at 3.82% CAGR by 2022-2027 | 108 Report Pages

Source from : MarketWatch - 13 days ago

The global General Anesthesia Drugs market size is expected to expand at a CAGR of 3.82% during the forecast period, reaching USD 9140.59 million by 2027 was valued at USD 7301.44 million in 2021.See details»


FSNUF Fresenius SE & Co. KGaA

Source from : Seeking Alpha - 9 days ago

To ensure this doesnโ€™t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»


Fresenius SE & Co KGaA (FRE) NPV

Source from : Hargreaves Lansdown - 6 days ago

All dividend data is calculated excluding any special dividends. Historical dividends may be adjusted to reflect any subsequent rights issues and corporate actions. The London Stock Exchange does ...See details»


Fresenius Medical Care AG & Co KGaA

Source from : Reuters - 2 years ago

Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD ...See details»